Impact of Pharmacogenomic Testing in the Management of Chronic Pain in Children


About this study

The purpose of this study is to:

  1. Assess outcome differences in two groups of pediatric patients with chronic pain.

  2. Review the perceived effectiveness and clinical utility of PGx testing on medical decision making in the management of children with chronic pain by discussing differences in pre and post-PGx testing plan of care recommendations.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Persistent chronic pain symptoms without evidence of current underlying organic pathology.
  • Persistent functionally limiting symptoms secondary to chronic pain that include, but are not limited to; fatigue, impaired activities of daily living, poor physical activity levels, and decreased school attendance.
  • Patient’s may present analgesic naïve or have been on previous medication trials, but experienced either adverse effects or no improvement in symptoms.

Exclusion Criteria: 

  • Children who do not have research authorization in their chart.  
  • Patients with no medication changes or recommendations as part of treatment plan.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Bradford Landry, D.O.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer